STAT

An interview with Robert Kennedy Jr. on vaccines

The environmental activist and leading vaccine skeptic says he has met with a series of Trump administration officials at the request of the White House.
Robert F. Kennedy Jr. talks with reporters in the lobby of Trump Tower in January 2017.

In the early days of 2017, proponents of vaccination were deeply concerned. Donald Trump, who has long espoused a debunked link between vaccines and autism, was set to enter the White House. He met with environmental activist Robert Kennedy Jr., who has for years argued that vaccines can cause a range of developmental and other health conditions. Kennedy emerged to report he’d been asked to chair a commission into vaccine safety.

But seven months later, no such commission has been appointed and the crisis-mired White House has declined to say whether the plan has been shelved.

STAT contacted Kennedy to see where plans stood. He would only speak on condition that STAT publish the interview in a Q&A format. He argued that his assertions — which are disputed as a misreading of the scientific literature by many mainstream scientists — have been misquoted and misrepresented in the media.

Here is STAT’s conversation with Kennedy. It has been lightly edited, for length and readability.

The question I want to ask you relates to the vaccine safety commission that you had announced in January that you were going to head, after you met with then President-elect Trump. It’s been a number

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
STAT1 min read
USDA Faulted For Disclosing Scant Information About Outbreaks Of H5N1 Avian Flu In Cattle
With 28 herds in eight states infected with H5N1 bird flu, scientists are calling on the U.S. to release more data to help them assess the risk.
STAT1 min read
Opinion: STAT+: How AI Can Help Satisfy FDA’s Drug, Device Diversity Requirements
To meet the Food and Drug Omnibus Reform Act, companies must rethink their current clinical trial strategies. Including AI and machine learning approaches can help.

Related Books & Audiobooks